Blood Purification Therapy With Dual-cannula in Jugular-femoral Venous

Preliminary Study on the Effect of Blood Purification Therapy With Dual-cannula in Jugular-femoral Venous

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05510713

Enrollment

Registered

2022-08-22

Start date

2022-09-01

Completion date

2024-10-01

Last updated

2022-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Purification, Dual-cannula, Vena Cava Disconnection

Brief summary

Acute kidney failure (AKI) is one of the most important causes of morbidity and mortality for critical ill patients. The use of blood purification treatment such as renal replacement therapy (CRRT) and plasma exchange has gradually developed into an effective treatment. However, the efficiency of blood purification may be affected by the recirculation of dual-lumen venous catheter for some special patients including patients with vena cava reflux disorder from massive occupations or ascites. For extreme cases like patients with vena cava disconnection or severe obstruction, the traditional blood purification treatment cannot work effectively. Thus, we used the dual-cannula in jugular-femoral venous blood purification therapy in the following two patients and found that it can improve the perfusion of systemic circulation and the prognosis of patients

Interventions

DEVICEHemodialysis Catheter

We add a dialysis catheter to the patient, i.e., replace single-cannula in femoral venous with dual-cannula in jugular-femoral venous

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* 1\. patients requiring haemodilution therapy for various reasons (acute renal failure, acute liver failure, etc.) * 2\. presence of superior vena cava and/or inferior vena cava reflux disorders * 3\. age greater than 18 years

Exclusion criteria

* 1\. Inability to establish suitable vascular access * 2\. Pregnant women * 3\. Not agreeing to active life support treatment * 4\. Severe active bleeding

Design outcomes

Primary

Measure	Time frame	Description
vasoactive drugs	144 hours after dual-cannula in jugular-femoral venous	doses of vasoactive drugs
ICU mortality	28-day ICU mortality	Measurement of ICU mortality

Secondary

Measure	Time frame	Description
Cytokine	24hous after dual-cannula in jugular-femoral venous	Checking cytokine levels by laboratory

Contacts

Primary ContactZhunyong Gu

gu.zhunyong@zs-hospital.sh.cn8613918677995

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026